Antibodyedrug conjugates (ADCs) are tripartite molecules consisting of a monoclonal antibody, a covalent linker, and a cytotoxic payload. ADC development has aimed to target the specificity inherent in antigeneantibody interactions to deliver potent cytotoxins preferentially to tumor cells and maximize antitumor activity and simultaneously minimize offtarget toxicity. The earliest ADCs provided disappointing results in the clinic; however, the lessons learned regarding the need for human or humanized antibodies, more stable linkers, and greater potency payloads led to improved ADCs. Three ADCs, gemtuzumab ozogamicin, brentuximab vedotin (BV), and inotuzumab ozogamicin, have been approved for hematologic malignancies. Site-specific conjugation methods have now resulted in a new generation of more uniform, molecularly defined ADCs. These are expected to display improved in vivo properties and have recently entered the clinic. We reviewed investigational ADCs currently in clinical testing for the treatment of B-cell lineage malignancies, including leukemias, lymphomas, and multiple myeloma. The rationales for antigen targeting, data reported to date, current trial status, and preclinical results for several newer ADCs expected to enter first-in-human studies are presented. Owing to the large number of ongoing and reported BV clinical studies, only the studies of BV for diffuse large B-cell lymphoma and those combining BV with checkpoint inhibitors in B-lineage malignancies have been reviewed. With > 40 ongoing clinical trials and 7 investigational ADCs already having advanced to phase II studies, the role of ADCs in the armamentarium for the treatment of B-lineage malignancies continues to be elucidated.
Introduction
B-cell lineage malignancies constitute a heterogeneous group of lymphomas, leukemias, and myelomas. Although many novel agents are being developed for these malignancies, many remain incurable with current therapies. The unmet need is especially notable among patients with relapsed or refractory (R/R) disease and among elderly patients unable to tolerate aggressive chemoimmunotherapy.
One class of agents being increasingly investigated in this context are antibodyedrug conjugates (ADCs). These are tripartite molecules consisting of a targeted monoclonal antibody (mAb), a covalent linker, and a cytotoxic payload (Figure 1 ). On binding to the cognate antigen on the surface of tumor cells, the antigeneADC complex is internalized and the cytotoxic payload released, resulting in cell death ( Figure 2 ). Using the specificity inherent in antibodyeantigen interactions to deliver cytotoxins preferentially to tumor cells, ADCs hold the promise of maximizing efficacy and minimizing toxicity. In practice, many factors have been shown to influence ADC safety and efficacy, especially the choice of the individual ADC components (antibody, linker, and payload) and the type of conjugation used. [1] [2] [3] [4] 
Factors Associated With ADC Efficacy and Safety
The success of an ADC is critically dependent on the choice of the targeted antigen, which should be highly expressed on target cells, with minimal expression elsewhere. With few exceptions, 5 internalization of the ADCeantigen complex is required. A highaffinity, fully human or humanized antibody is preferred. The choice of a linker is also critical. In vivo, linkers must be sufficiently stable to processes such as hydrolysis and glutathione deconjugation to prevent the systemic release of the cytotoxic payload but must still be sufficiently labile to release the payload within the tumor cells. This can be accomplished through the choice of a cleavable linker (eg, containing valine-citrulline, a substrate for lysosomal cathepsin B) or a noncleavable linker, which depends on degradation of the antibody to release the payload.
Because each ADC molecule carries a limited number of payloads, these generally require high cytotoxicity (typically subnanomolar potency). The payload potency, however, must be balanced against target-independent associated adverse events (AEs).
To date, most ADC payloads have been in 2 mechanistic classes. The first of these comprises antimitotic payloads, including the auristatins (MMAE [vedotin] and MMAF [mafodotin] ) and maytansines (DM1 [emtansine, mertansine], DM4 [ravtansine] ). These bind to tubulin, resulting in G 2 /M arrest and subsequent apoptosis. When attached to cleavable linkers, ADCs containing these antitubulin agents have frequently been associated with peripheral neuropathy. When attached to noncleavable linkers, such ADCs tend to be associated with hematologic toxicities. With either type of linker, ocular toxicities such as keratitis have also been noted across multiple diverse target antigens, suggesting that these toxicities are related to the free drug in circulation rather than the binding of ADCs to corneal cells. 6 The second mechanistic class of payloads is composed of agents that bind to DNA, including the calicheamicins (ozogamicins), which induce DNA double-strand breaks. In clinical trials, calicheamicin-containing ADCs have been associated with thrombocytopenia and hepatic sinusoidal obstructive syndrome (SOS; veno-occlusive disease), 7 in particular, in patients undergoing stem cell transplantation (SCT). SOS is believed to be caused by calicheamicin-induced sinusoidal endothelial cell toxicity. 8 PBD (pyrrolobenzodiazepine) dimers (talirine, tesirine) constitute another type of DNA-binding payload. They bind sequence selectively, resulting in crosslinked DNA. At present, the clinical data for ADCs with this type of payload are limited; however, AEs, including thrombocytopenia, neutropenia, maculopapular rash, and liver function abnormalities, have been reported. 9 In addition to antigen target selection and ADC constituent parts, the method of linkerepayload conjugation to the antibody plays an important role in determining the clinical properties of an ADC. To date, most ADCs have been prepared by nonspecific attachment of the linker to available cysteine or lysine residues on the antibody, thereby producing ADC mixtures with the payload linked at a variety of different sites with a range of drug-to-antibody ratios (DARs), including a DAR of 0 for the "naked" (unconjugated) antibody ( Figure 3) . The individual components of these mixtures have distinct pharmacokinetics, efficacies, and safety profiles, 10 in many cases resulting in suboptimal in vivo properties.
More recently, site-specific conjugation methods capable of producing near-homogeneous ADCs with defined DARs have been introduced ( Figure 3) . In animal models, some ADCs produced in this way have demonstrated improved stability, better in vivo properties, and the potential for larger therapeutic windows.
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ADC Evolution
ADCs developed in the 1970s through the 1990s generally provided disappointing clinical results. 12 The payloads were commonly used chemotherapeutic drugs such as 5-fluorouracil and doxorubicin, which most likely lacked sufficient potency. 13 Other problems included the selection of appropriate antigens, the use of murine antibodies, and inadequate linker stability. The lessons learned subsequently led to ADCs having somewhat improved therapeutic windows. Among these was the CD33-targeted ADC gemtuzumab ozogamicin, which received its first Food and Drug Administration (FDA) approval for use in acute myeloid leukemia in 2000. 14 Later, another ADC, brentuximab vedotin (BV), 15 was approved for certain Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma indications. Inotuzumab ozogamicin was approved for treatment of adults with R/R B-cell precursor acute lymphoblastic leukemia (ALL) in 2017, becoming the third ADC to be approved for a hematologic indication. In recent years, the development of site-specific conjugation technologies has defined a new generation of ADCs. Agents of this type, such as polatuzumab vedotin (PoV) for non-HL (NHL), 16 have now begun to enter the clinic, 6 thereby allowing real-world testing of the hypothesis that their improved properties will overcome the limitations on the therapeutic index seen with earlier ADCs.
Objective, Methods, and Organization
Advances in ADC technology, along with the many ADCs now being evaluated, add to the difficulty of assimilating evidence on the role of this class of agents in hematologic malignancies. To provide a current overview, we have reviewed all ADCs currently undergoing clinical investigation in B-lineage malignancies found through searches of PubMed, ClinicalTrials.gov, and the 2014 to 2017 abstracts from the American Association for Cancer Research, American Society of Clinical Oncology, American Society of Hematology, and European Hematology Association annual meetings and the 2017 International Conference on Malignant Lymphoma. ADCs for the treatment of B-cell leukemias, B-cell lymphomas, and multiple myeloma (MM) were reviewed separately, although in some cases, the same agent might be under investigation for > 1 disease type. Because of the large number of trials and reports for BV, we reviewed only clinical studies of BV for diffuse large B-cell lymphoma (DLBCL) or B-lineage malignancies combined with checkpoint inhibitors.
Investigational ADCs for B-cell Leukemias
Anti-CD19 ADCs CD19 is a type I transmembrane protein expressed in both normal and neoplastic B cells and in follicular dendritic cells. 17 It functions as a costimulator of the B-cell receptor (BCR) complex, which also has BCR-independent effects. To date, 2 ADCs targeting CD19 have reached clinical development for ALL, denintuzumab mafodotin (SGN-CD19A) and coltuximab ravtansine (SAR3419; Table 1 ). In a phase I study of patients with heavily pretreated B-ALL, single-agent denintuzumab mafodotin provided a 35% composite complete response (CRc) rate, with a median duration of response (mDOR) of 27 weeks (Table 2) . 19 Approximately 50% of patients experienced pyrexia, nausea, and fatigue. Notably, 56% experienced symptoms of ocular toxicity, which has also been associated with other ADCs using tubulin-binding payloads. A phase II study of single-agent coltuximab ravtansine for R/R ALL reported an overall response rate (ORR) of 26%, with an mDOR of 1.9 months. 20 The incidence rates of grade 3/4 thrombocytopenia, neutropenia, and leukopenia were 84%, 68%, and 68%, respectively. Approximately 25% of patients experienced ocular toxicity, all grade 1 or 2. The investigators concluded that coltuximab ravtansine has acceptable safety, but limited efficacy, for ALL. One other trial of an anti-CD19 ADC in B-ALL is ongoing (Supplemental Table 1 ; available in the online version). Loncastuximab tesirine (ADCT-402), 27 a humanized anti-CD19 mAb conjugated to a PBD dimer through a cleavable linker, is being ADCs for Treatment of B-lineage Malignancies studied in a phase I trial of patients with R/R B-ALL aged ! 12 years (ClinicalTrials.gov identifier, NCT02669264). The interim results from the ongoing dose escalation phase were recently reported. 18 Of the 29 evaluable patients (median previous therapies, 2), 4 (14%) achieved a complete bone marrow response. The most common grade ! 3 toxicities were febrile neutropenia (24%) and a decreased neutrophil count (14%).
Anti-CD22 ADCs
CD22, also known as Siglec-2, is a type I transmembrane sialoglycoprotein expressed on the cell surface of mature B-lymphocytes, with very limited expression elsewhere. One recent study found that CD22 was expressed in 100% of ALL cases, of which 95% showed expression in ! 90% of blasts. 28 CD22 exerts an inhibitory effect on BCR signaling. Binding to its cognate ligand leads to rapid internalization of the complex, with no evidence of shedding into the external environment, making it an attractive target for ADCs. Inotuzumab ozogamicin (InO) is a CD22-targeting ADC containing an acid-labile linker and a calicheamicin derivative as its payload. After CD22 binding and internalization, the linker is cleaved at the low lysosomal pH, releasing its payload, a DNA minor groove binder. 29 Clinical studies of children, 21 adults, 23, 24, 30 and older patients 31 have reported encouraging activity for InO in ALL when used alone or combined with chemotherapy (Table 2) . A phase II study of 90 patients with R/R B-ALL initially treated patients with 1.3 to 1.8 mg/m 2 of InO every 3 to 4 weeks. 23 A 58%
CRc rate was reported, along with AEs that included fever, hypotension, and liver function abnormalities. Based on preclinical studies indicating that lower, more frequent, dosing could result in improved efficacy and reduced toxicity, the dosing regimen was changed to 0.8 mg/m 2 on day 1 and 0.5 mg/m 2 on days 8 and 15 every 3 to 4 weeks ("weekly dosing"). 23 The response rates were similar in the weekly dosing group (CRc rate, 58%); however, the rates of fever (22% vs. 59%), hypotension (15% vs. 27%), and elevated aminotransferase (27% vs. 57%) were considerably lower compared with the initial cohort. Negative minimal residual disease (MRD) status was achieved by 41% and 39% of patients receiving the modified and original dosing regimens, respectively, with a median overall survival (OS) of 7.3 and 5.0 months, respectively. InO was examined in the phase III randomized INO-VATE (inotuzumab ozogamicin trial to investigate tolerability and efficacy) trial of 326 adults with R/R ALL. 24 Patients were randomized to InO (weekly dosing) or chemotherapy consisting of either FLAG (fludarabine, cytarabine, granulocyte colony-stimulating factor), cytarabine plus mitoxantrone, or high-dose cytarabine. The trial met 1 primary endpoint, a significantly improved complete response (CR) rate (81% vs. 29%; P < .001). Another primary endpoint, improvement in OS, was not met with the prespecified significance level of 0.0208 using the standard proportional hazard assumption 59 (59) R/R adult ALL InO, d3, q4w Â4 (C1-4) þ low-intensity CVD ORR, 78%; CR, 59%; mOS 11 mo SOS (15%), grade ! 3: prolonged thrombocytopenia (81%), infections (73%) Abbreviations: ALL ¼ acute lymphoblastic leukemia; ALT ¼ alanine transaminase; AST ¼ aspartate aminotransferase; B ¼ B-cell; BM ¼ bone marrow; C ¼ cycle; CR ¼ complete response; CRc ¼ composite complete response; CRi ¼ complete remission with incomplete hematologic recovery; CRp ¼ complete response with incomplete platelet recovery; CVD ¼ cisplatin, vinblastine, dacarbazine; FLAG ¼ fludarabine, cytarabine, granulocyte colony-stimulating factor; HD ¼ high-dose; InO ¼ inotuzumab ozogamicin; L ¼ line; LBL ¼ precursor B-cell lymphoblastic lymphoma; LL ¼ leukemia lymphoma; mDOR ¼ median duration of response; mOS ¼ median overall survival; mPFS ¼ median progression-free survival; MRD ¼ minimal residual disease; NA ¼ not available; ORR ¼ overall response rate; qw ¼ once weekly; q3w ¼ once every 3 weeks; q4w ¼ once every 4 weeks; R/R ¼ relapsed or refractory; SAR3419 ¼ coltuximab ravtansine; sd ¼ single dose; SGN-CD19A ¼ denintuzumab mafodotin; SOS ¼ sinusoidal obstructive syndrome. a Data presented as safety population (evaluable efficacy population). b All ADCs were administered intravenously. c Combination trials.
(7.7 vs. 6.7 months; hazard ratio, 0.77; P ¼ .04). However, OS was significantly improved by InO in an exploratory post hoc analysis. The significant CR benefit of InO extended to all groups, except for the Philadelphia chromosome-positive and t(4;11)-positive subgroups. MRD negativity and progression-free survival (PFS) were significantly improved in the InO arm, and significantly more patients were able to proceed directly to SCT in that arm (41% vs. 11%; P < .001). Liver-related AEs were more common in the InO group, with SOS reported in 11% compared with 1% of patients in the chemotherapy arm. Among the 48 patients treated with InO who underwent post-study SCT, 10 (21%) developed SOS. With the results of this trial, the FDA recently approved InO for treating adults with R/R B-cell precursor ALL, 32 and the European Medicines Agency granted approval for use as monotherapy in adults with CD22 þ R/R B-cell precursor ALL. 33 Studies of InO combined with chemotherapy for ALL have also been reported. A phase I/II trial of frontline InO combined with mini-hyper-CVD (cyclophosphamide, vincristine, dacarbazine; and rituximab in patients with CD20 þ disease), followed by maintenance therapy for patients aged > 60 years with ALL, reported that 42 of 43 response-evaluable patients (98%) achieved a CR, complete remission with incomplete platelet recovery, or complete remission with incomplete hematologic recovery. 25 The MRD negativity rate was 96%, and the 3-year OS rate was 54%.
Relatively high rates of grade ! 3 prolonged thrombocytopenia and infection were observed, with SOS occurring in 9% of patients. The investigators concluded that this regimen appears to be superior to hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) for frontline treatment of older patients with ALL. InO combined with mini-hyper-CVD was also investigated in the salvage setting for adult ALL. 26 The ORR was 78% (CR, 59%), with 82% of responders achieving MRD negativity. Approximately 44% of patients proceeded to allogeneic SCT. Grade ! 3 AEs were primarily hematologic. SOS occurred in 9 patients (15%), all of whom had undergone allogeneic SCT before (n ¼ 3), after (n ¼ 5), or before and after (n ¼ 1) InO therapy. Investigators concluded that the risk of SOS should be considered carefully for patients with previous liver damage and those who are transplant candidates. Currently, 2 single-agent and 5 combination trials of InO for B-ALL are recruiting, with additional studies planned or underway (Supplemental Tables 1 and 2 ; available in the online version).
Anti-CD25 ADCs
CD25, also known as IL2R-a (interleukin-2 receptor-a) is a type I transmembrane protein that comprises the a-subunit of the IL-2 receptor. Except for regulatory T cells and activated T cells, CD25 is rarely expressed in normal cells. However, it is found in Reed-Sternberg cells and adjacent cells in the microenvironment in HL and in many B-cell and T-cell malignancies. 34, 35 An ADC targeting CD25, camidanlumab tesirine (ADCT-301), consists of an anti-CD25 antibody linked to a PBD dimer payload by way of a protease-sensitive linker. 36 This agent is currently undergoing study in clinical trials in R/R CD25 þ ALL, acute myeloid leukemia, HL, and NHL (Supplemental Table 1 ; available in the online version).
The results for ALL have not yet been reported.
Investigational ADCs for B-lineage Lymphomas
Anti-CD19 ADCs
The previously described anti-CD19 ADCs denintuzumab mafodotin, coltuximab ravtansine, and loncastuximab tesirine have also undergone clinical testing to treat lymphomas. In a phase I trial in patients with B-NHL, which included patients with DLBCL previously treated with intensive salvage therapy, denintuzumab mafodotin provided a 33% ORR (22% CR), with an mDOR of 40 weeks (Table 3) . 37 Superficial microcystic keratopathy was observed in 84% of patients but was reported to be manageable with topical steroids and dose modifications. The results of that trial led to a phase II trial of denintuzumab mafodotin combined with RICE (rituximab, ifosfamide, carboplatin, etoposide, mesna) for secondline DLBCL (ClinicalTrials.gov identifier, NCT02592876; Supplemental Table 2 ; available in the online version). Four phase I or II studies have reported the results for coltuximab ravtansine in B-cell lymphomas, with ORRs ranging from 17% to 44% (Table 3) . A phase I study examined the optimal dosing of coltuximab ravtansine in 44 patients with B-NHL. 40 The study found the best safety profile consistent with antilymphoma activity was obtained when dosing once weekly for 4 weeks, followed by once every 2 weeks for the next 4 doses. 40 The phase II STARLYTE (SAR3419 as single agent in relapsed-refractory DLBCL patients) study of single-agent coltuximab ravtansine in 41 patients with CD19 þ R/R DLBCL reported a 44% ORR (12% CR) with moderate hematologic toxicity and ocular disorders and peripheral neuropathy of grade 1 or 2 only. 39 A phase II study of coltuximab ravtansine combined with rituximab in 52 patients with R/R DLBCL using the qw/q2w (once weekly for 4 weeks, followed by once every 2 weeks for the next 4 doses) schedule did not reach the prespecified outcome (ORR ! 40%), possibly owing to the inclusion of many patients with disease refractory to first-line therapy. 42 The interim results from a study of single-agent loncastuximab tesirine (ADCT-402) in R/R B-NHL were recently reported. 41 At a point at which the maximum tolerated dose (MTD) had not yet been reached, the response rate in 68 evaluable patients receiving ! 120 mg/kg was 60% (35% CR). Among the 49 patients with DLBCL receiving ! 120 mg/kg, the ORR was 55% (37% CR). The most common grade ! 3 AEs were decreased neutrophil count (15%) and elevated g-glutamyltransferase (15%). Skin-related changes occurred in 52% of the patients. Another anti-CD19 ADC, huB4-DGN462, was recently reported to have promising activity in xenograft models of lymphoma (Supplemental Table 3 ; available in the online version). 69 
Anti-CD22 ADCs
Pinatuzumab vedotin (PiV; DCDT2980S) is an anti-CD22 ADC containing a protease-cleavable linker attached to the microtubule inhibitor monomethyl auristatin E (Table 1) . 70 A phase I study investigated PiV with and without rituximab in 75 patients with R/R DLBCL, indolent NHL, or chronic lymphocytic leukemia (CLL). 43 For refractory DLBCL, the response rates for the single-agent and the combination were 25% and 17%, respectively. For indolent NHL, the corresponding response rates for the single agent and the combination were 42% and 33%. No responses were
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Clinical Lymphoma, Myeloma & Leukemia July 2018 -457 seen in the 10 patients with CLL, although it was noted that the MTD for PiV had not been reached in these patients. Among all patients, the most common AEs were fatigue, neutropenia, and peripheral sensory neuropathy, the last of which led to treatment discontinuation for 15% of the patients. ROMULUS (a study of PiV combined with rituximab or PoV combined with rituximab or obinutuzumab in participants with R/R B-cell NHL; ClinicalTrials.gov identifier, NCT01691898) is a randomized phase II study that includes an arm in which PiV is combined with anti-CD20 antibodies for the treatment of R/R DLBCL or follicular lymphoma (FL). 16 The response rates in the PiV/rituximab arm were 57% (24% CR) for DLBCL and 62% (10% CR) for FL, with an mDOR for DLBCL of 5.2 months. AEs included fatigue (55%), peripheral neuropathy (39%), and neutropenia (27% 48 At the MTD, encouraging response rates were observed in those with relapsed DLBCL (74%) or relapsed FL (87%) but not in those with transformed FL or mantle cell lymphoma (MCL), leading to the conclusion that InO did not appear to overcome rituximab resistance in this group. Discontinuations because of AEs occurred in 49% of the patients. A phase II study of R-InO, followed by high-dose therapy and autologous SCT, in 63 patients with high-risk R/R DLBCL reported a 29% ORR after 3 cycles of R-InO, indicating lower than expected activity as a salvage regimen. 49 A randomized phase III trial compared R-InO with either R-bendamustine or R-gemcitabine in 338 patients with high-risk CD22 þ aggressive NHL who were not candidates for high-dose chemotherapy. 50 No significant difference was found in ORR, PFS, or OS between the groups, but a greater percentage of patients in the R-InO arm discontinued because of AEs (32% vs. 17%). More encouraging results were obtained in a phase I trial of the combination of InO with R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone) in R/R B-NHL. 46 Among the 27 patients with indolent lymphoma, the ORR was 100%, and 57% of those with aggressive lymphoma had an objective response. The toxicities were primarily hematologic. No trials are currently investigating InO alone or combined with rituximab in NHL; however, studies of the combination of InO with chemotherapy (ClinicalTrials.gov identifier, NCT01664910) and with R-CVP (ClinicalTrials.gov identifier, NCT01679119) in B-NHL are currently recruiting (Supplemental Table 2 ; available in the online version). Also, the preclinical results for ADCs consisting of epratuzumab (hLL2-PBD) 71 and a cysteine-engineered version of epratuzumab (ADCT-602, hLL2-Cys-PBD) 72 conjugated to a PBD dimer through a protease-cleavable linker have been reported (Supplemental Table 1 ; available in the online version). Both compounds were active in multiple lymphoma models, with the latter resulting in rapid B-cell depletion (a biomarker of pharmacodynamics effects) in cynomolgus monkeys.
Anti-CD25 ADCs
The interim results from a first-in-human study of the anti-CD25 ADC camidanlumab tesirine were recently reported. 9 In the 21 evaluable patients with B-NHL (DLBCL and MCL), the ORR was 19% (9.5% CR). Among the 12 patients with HL treated at the 45-mg/kg dose level, however, the ORR was 100% (50% CR). The most common grade ! 3 AEs were elevated g-glutamyltransferase (13%) and a decreased platelet count (9%). Dose-limiting toxicities included oral mucositis and small bowel enteritis, elevated creatinine phosphokinase, maculopapular rash and pruritus, and lip ulceration and skin infection.
Anti-CD30 ADCs
CD30 is a member of the tumor necrosis factor (TNF) receptor superfamily and is primarily expressed in Hodgkin Reed-Sternberg cells in classic HL (cHL), in anaplastic large-cell lymphoma, and in a subset of DLBCL. 73 BV, an ADC consisting of an anti-CD30
antibody, a cleavable linker, and an MMAE payload (Table 1) , has proved to be highly active and well tolerated in HL. It has been approved for use in patients with cHL after failure of autologous hematopoietic SCT (auto-HSCT) or ! 2 previous multiagent chemotherapy regimens who are not auto-HSCT candidates, for post auto-HSCT consolidation chemotherapy in patients with cHL at high risk of relapse or progression, and for previously untreated stage III or IV cHL combined with chemotherapy. As a single agent, BV was associated with a 75% ORR (34% CR) in a phase II pivotal study in patients with R/R HL. 74 When used as part of consolidation therapy after auto-HSCT in patients with high-risk R/R HL, BV led to a significant improvement in the median PFS (42.9 vs. 24 months; P ¼ .0013). 75 Approval for frontline use in combination with chemotherapy was based on the randomized phase III ECHELON-1 study, which found significantly improved modified PFS for the combination of BV with AVD (doxorubicin, vinblastine, dacarbazine) compared with standard bleomycin combined with AVD (hazard ratio for progression, death, or modified progression, 0.77; P ¼ .03). 76 BV has been widely investigated in B-lineage malignancies and has been extensively reviewed. 15, 77 We have focused on its combination with checkpoint inhibitors in B-lineage malignancies and its investigational uses in DLBCL. A strong rationale exists for combining BV with checkpoint inhibitors. In vitro experiments have served to elucidate a process known as immunogenic cell death (ICD). ICD is induced by some, but not all, cytotoxic compounds, including auristatins. In ICD, cell surface composition changes and soluble mediators known as damage-associated molecular patterns are released. 78 These, in turn, promote dendritic cell maturation and activation, thereby stimulating immune response to other tumor cells. Cellular experiments
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have shown that BV-mediated microtubule disruption leads to ICD, resulting in an inflammatory phenotype and activation of innate immunity. 79 Xenograft studies found this immune response to be further potentiated by anti-programmed cell death 1 therapy. 80 Encouraging results for the combination of BV with checkpoint inhibitors in clinical HL studies have been reported. The interim results from a phase I/II study of BV combined with the programmed cell death 1 inhibitor nivolumab as initial salvage therapy for patients with R/R cHL demonstrated an ORR of 82% in all 61 treated patients, with a 61% CR rate. 57 Infusion-related reactions occurred in 44%. However, nearly all were mild and did not preclude administration of therapy, and only 8% of patients required systemic steroids for immune-related AEs. BV plus nivolumab therapy did not appreciably affect stem cell mobilization in patients proceeding to auto-HSCT. Another study investigated the same combination in patients with R/R HL of any line (median, 3 previous treatments). 56 An 89% ORR (50% CR) was reported for the 18 evaluable patients, and the 6-month PFS rate was 91%. Two cases of grade ! 3 pneumonitis (11%), 1 of which was grade 5, were reported. No data from the trials of BV combined with a checkpoint inhibitor in NHL have yet been reported; however, a study of BV combined with nivolumab (Checkmate 436) is currently ongoing (Supplemental Table 2 ; available in the online version), as are a number of studies of single-agent BV in NHL (Supplemental Table 1 ; available in the online version) and BV combined with checkpoint inhibitors in cHL (Supplemental Table 2 ; available in the online version). A phase II study exploring the use of BV in R/R B-and T-cell lymphomas included a cohort of patients with DLBCL who were treated with BV alone or BV combined with rituximab. 52 For the 48 evaluable DLBCL patients treated with single-agent BV, the ORR was 44% (17% CR); among those with transformed disease, the ORR was 50%. Although CD30 positivity by visual assessment at institutional laboratories was required for inclusion, computerassisted central review later found that 5 of 49 patients had 0% CD30 expression. No clear correlation was found between CD30 expression and response; however, the response appeared to require some degree of CD30 expression. In another phase II study, BV was combined with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in frontline treatment of CD30 þ patients with high-intermediate/high-risk DLBCL. 54 The preliminary results were encouraging, with an ORR of 91% (82% CR) in 11 treated patients. The AEs included peripheral sensory neuropathy (55%).
Anti-CD37 ADCs
CD37 is a member of the tetraspanin family found on pre-B and mature B cells (but not plasma cells), which mediates apoptotic cell signaling and is important for B-celleT-cell interactions. 81 Among patients with de novo DLBCL, CD37 þ status has been reported to predict for improved survival and was superior to other prognostic factors, including International Prognostic Index score, cell of origin, nodal/extranodal primary origin, and other factors. 82 Two
ADCs targeting CD37 have advanced to clinical testing (Table 1) . Naratuximab emtansine (IMGN529) is an anti-CD37 antibody conjugated by an SMCC [succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate] linker to the maytansinoid DM1. 83 Preliminary results from a phase I study of single-agent naratuximab emtansine in R/R B-NHL that had not yet arrived at the MTD have been reported. 59 That study noted early-onset neutropenia, which investigators attributed to cytokine release and found to be treatable using peri-infusional steroids, and a CD37-mediated reduction in lymphocytes. The ORR was 13%, and no immunogenicity against the antibody or DM1 component of the ADC was detected. Preclinical data suggested that CD20 binding might enhance IMGN529 internalization and degradation, leading to greater amounts of cytotoxin release and potentially synergistic effects. 84 A trial of naratuximab emtansine combined with rituximab in patients with R/R NHL (ClinicalTrials.gov identifier, NCT02564744; Supplemental Table 2 ; available in the online version) is currently recruiting. AGS67E consists of an anti-CD37 antibody conjugated to MME by a protease-cleavable linker. 85 During dose escalation in a first-inhuman phase I study of patients with B-and T-cell malignancies, signs of AGS67E activity were seen, including a 23% ORR (18% CR) in the 22 patients with DLBCL. 58 Currently, the combination of naratuximab emtansine and rituximab is being explored in NHL (Supplemental Table 2 ; available in the online version) and the first-in-human AGS67E trial continues recruitment.
Anti-CD70 ADCs
CD70 is a member of the TNF superfamily and acts as a ligand for CD27 and regulates B-and T-cell function. It is highly expressed in B-and T-cell lymphomas and some solid tumors. In both subtypes, activated B cell (ABC) and germinal center B cell (GCB), of DLBCL, high CD70 expression has been associated with shorter OS. 86 In FL, a high number of CD70-expressing T cells has also been associated with inferior OS. 87 Three ADCs targeting CD70 have reached clinical development in lymphoma to date (Table 1) . However, all were subsequently discontinued. Vorsetuzumab mafodotin (SGN-75) is an anti-CD70 humanized mAb conjugated to MMAF using a noncleavable linker. 88 Toxicity concerns were raised in a phase I dose escalation trial of CD70 þ R/R NHL or metastatic renal cell carcinoma (RCC), because idiopathic thrombocytopenia purpura developed in 2 of the NHL patients. 61 MDX-1203 (BMS-936561) is a fully human anti-CD70 antibody conjugated to a duocarmycin derivative through a protease-cleavable linker. A first-in-human study in patients with CD70 þ B-NHL or advanced clear cell RCC reported dose-limiting toxicity of grade 3 hypersensitivity at the highest dose (15 mg/kg q3w). 60 At that dose, delayed toxicities of facial edema and pleural/pericardial effusions were reported in 38% of the patients. The best response was stable disease (69%), with no correlation with dose. SGN-CD70A is an ADC generated through site-specific conjugation of an anti-CD70 mAb containing engineered cysteine residues to a PBD dimer payload. 89 A phase I trial of SGN-CD70A for NHL and RCC (ClinicalTrials.gov identifier, NCT02216890) has been completed; however, the results have not yet been reported. In October 2016, the sponsor of the study noted that development of SGN-CD70A had been discontinued because of the results from a portfolio review and evaluation of phase I data. 90 Although preclinical characterization of other optimized anti-CD70 ADCs has been reported (Supplemental Table 3 ; available in the online version), 91 no clinical trials of anti-CD70 ADCs are currently ongoing.
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Anti-CD74 ADCs CD74, also known as invariant chain (Ii), is a type II transmembrane glycoprotein involved in major histocompatibility complex class II antigen presentation, B-cell maturation, T-cell responses, and macrophage migration inhibitory factor-induced signaling. 92 Its overexpression in most cases of NHL and myelomas and its rapid internalization have made it a promising target for ADCs. 93 Table 3 ; available in the online version). Each consists of an aglycosylated human anti-CD74 antibody conjugated to a dibenzocyclooctyl (DBCO)emaytansinoid payload at specific sites determined to confer the greatest in vivo stability. 94, 95 Both demonstrated antitumor effects in xenograft models of myeloma and B-cell llymphoma. 63 In the SU-DHL-6 model of B-NHL, STRO-001 combined with BR (bendamustine, rituximab) significantly improved tumor suppression relative to BR alone (P ¼ .02). 96 STRO-001 depleted normal B cells in cynomolgus monkeys, consistent with the intended pharmacodynamic effect. A first-in-human study of STRO-001 in advanced B-NHL and MM (ClinicalTrials.gov identifier, NCT03424603) recently began dosing patients (Table 3) . 97 
Anti-CD79b ADCs
CD79b is a component of the BCR complex that drives receptor signaling. Its expression is limited to mature B cells, and it is ubiquitously expressed in CLL and NHL. 98 In DLBCL 99 and FL, CD79b is frequently mutated, and its overexpression in DLBCL has been associated with primary resistance to ibrutinib. 100 Polatuzumab vedotin (PoV) is an ADC consisting of an anti-CD79b antibody site-specifically conjugated to MMAE through a protease-cleavable linker. 98 More recently, iladatuzumab vedotin (DCDS0780A), another CD79b ADC also consisting of a humanized anti-CD79b IgG antibody conjugated to an MMAE through a protease labile linker, has entered the clinic. A summary of studies using these agents as monotherapy or combined with other agents in NHL is presented in Table 3 . In a phase I study, 95 patients with either R/R NHL or CLL, for whom no suitable curative or higher priority therapy existed, were treated with PoV alone (n ¼ 86) or combined with rituximab (n ¼ 9). 63 In the monotherapy group treated at the recommended phase II dose, which consisted of 16, 27, and 2 patients with indolent NHL (FL, MZL, or SLL), DLBCL, and MCL, respectively, the ORR was 55% (median PFS, 5.7 months), including an ORR of 56% (median PFS, 5.0 months) in activity-evaluable DLBCL patients. The ORR was 78% (22% CR) in NHL patients treated with the combination. No responses were seen in patients with CLL. The investigators suggested this likely resulted from lower exposure and faster clearance in those patients relative to the NHL patients. Peripheral sensory neuropathy was reported in 37% and 67% of patients in the monotherapy and combination therapy cohorts, respectively. The previously described ROMULUS trial (ClinicalTrials.gov identifier, NCT01691898) is a randomized phase II study of the anti-CD22 ADC PiV or the anti-CD79B ADC PoV combined with an anti-CD20 mAb (either rituximab or obinutuzumab) in R/R DLBCL and FL. The combination of PoV with rituximab was associated with a 56% ORR (15% CR) in patients with DLBCL (median, 3 previous treatments) and a 70% ORR (40% CR) in those with FL (median, 2 previous treatments). 16 In the PoV arm, reversible peripheral neuropathy was reported in 39% of the patients and was a frequent reason for discontinuation. The combination of PoV with obinutuzumab alone is being studied in patients with R/R DLBCL or FL in an ongoing phase I/II trial. 65 Among the efficacy-evaluable patients (21 with DLBCL, 23
with FL), the best response rates were 52% (29% CR) and 78% (30% CR) in the DLBCL and FL patients, respectively. In an ongoing phase I/II study, patients with R/R DLBCL or FL who are not candidates for HSCT are treated with PoV, an anti-CD20 mAb (either rituximab or obinutuzumab), and bendamustine. The interim results for PoV combined with BR reported an ORR of 100% (67% CR) in FL (n ¼ 6). 67 Recently, the study was reported to have met its primary endpoint. 101 Among the 80 evaluable patients with DLBCL, the addition of PoV to BR significantly improved the CR rate (40% vs. 15%; P ¼ .012) and median OS (11.8 vs. 4.7 months; P ¼ .0008), resulting in a 65% reduction in the risk of death relative to BR alone. Grade 3/4 cytopenias were common; treatment-emergent neuropathy occurred in 38.5% of patients. Based on these results, PoV was granted breakthrough therapy designation by the US FDA and PRIME designation by the European Medicines Agency for the treatment of R/R DLBCL. Because of the tolerability and antitumor effects observed with PoV, the combination of PoV with R-CHP and G-CHP (obinutuzumab plus cyclophosphamide, doxorubicin, prednisone) is being investigated in patients with newly diagnosed or R/R DLBCL. In 45 previously untreated patients who received PoV combined with R-CHP, the ORR was 91% (78% CR). 64 The ORRs were similar in those with ABC (91%) and GCB (86%) DLBCL. Neutropenia (27%) and febrile neutropenia (11%) were the most common grade ! 3 AEs. For PoV combined with G-CHP in patients with previously untreated DLBCL, the ORR was 91% (81% CR), with a median DOR > 10 months. 66 Peripheral neuropathy (all grade 1 or 2) occurred in 38% of patients. Clinical studies of PoV in DLBCL have not used a CD79b expression cutoff as an inclusion criterion. CD79b has been reported to be present in almost all cases of DLBCL. Its surface expression, however, did not significantly correlate with the clinical response to PoV in 1 study of 18 patients. 102 Six ongoing studies are investigating PoV in NHL (Supplemental Table 2 ; available in the online version), including its use in combination with lenalidomide (ClinicalTrials.gov identifier, NCT02600897), venetoclax (ClinicalTrials.gov identifier, NCT02611323), and the antiprogrammed cell death ligand 1 mAb atezolizumab (ClinicalTrials.gov identifier, NCT02729896). In addition, the international randomized, double-blind, placebo-controlled phase III POLARIX trial (ClinicalTrials.gov identifier, NCT03274492),
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þ previously untreated DLBCL to R-CHPþPoV(þplacebo vincristine) versus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; þplacebo PoV) is currently ongoing.
The preliminary results from a first-in-human phase 1 study of iladatuzumab vedotin with or without rituximab in patients with R/R B-NHL were recently reported. 68 In both the all-histologic type (n ¼ 44) and DLBCL (n ¼ 24) groups, the response rates (85% [57% CR] and 84% [54% CR], respectively) were somewhat greater for the rituximab combination. Among all patients with DLBCL (median, 3 previous therapies), the ORR was 60% (43% CR). Ocular toxicities occurred in 43% of the patients and were generally manageable through dose reductions or drug withdrawal.
The most frequent grade ! 3 AE was neutropenia (22%).
Investigational ADCs for Myeloma
Anti-CD56 ADCs CD56, also known as neural cell adhesion molecule 1 (NCAM1) is a type I plasma membrane glycoprotein normally expressed on neural tissues, natural killer (NK) cells, and a subset of T cells. Although not normally present on plasma cells, it is expressed on plasma cells in 70% to 80% of MM cases 103 and is also found in certain solid tumors such as neuroblastoma and small-cell lung cancer. Lorvotuzumab mertansine (IMGN901) consists of an anti-CD56 mAb conjugated to a maytansinoid payload by a stable disulfide linker (Table 1) . 104 In a phase I single-agent study (Table 4) , lorvotuzumab mertansine was associated with an 18% ORR in 28 evaluable patients with CD56 þ R/R MM, most of whom had received ! 6 previous therapies. 105 The treatment was well tolerated, with an 11% rate of grade ! 3 toxicity. Lorvotuzumab mertansine was combined with lenalidomide and dexamethasone in a phase I study of 44 patients with CD56þ R/R MM for whom the median number of previous therapies was 2. 106 The ORR was 59%
(6% CR/stringent CR), and no immunogenicity was detected. At the MTD for lorvotuzumab mertansine (75 mg/m 2 ), peripheral neuropathy occurred in 16% of the patients, and grade 3 tumor lysis syndrome occurred in 11%. In November 2013, the sponsor announced the discontinuation of lorvotuzumab mertansine for small-cell lung cancer owing to insufficient efficacy and an increased infection rate. 110 A phase II trial of lorvotuzumab mertansine for hematologic malignancies (ClinicalTrial.gov identifier, NCT02420873) has been completed, but the results have not yet been reported (Supplemental Table 1 ; available in the online version).
Anti-CD74 ADCs
A phase I study of milatuzumab doxorubicin (hLL1-DOX) in patients with R/R MM (ClinicalTrial.gov identifier, NCT01101594) has been completed, but the results have not yet been reported. As previously noted, a trial of STRO-001 to treat B-NHL and MM recently began dosing patients. 97 Anti-CD138 ADCs CD138 (syndecan-1), a type I transmembrane proteoglycan cell adhesion molecule expressed on plasma cells, is a primary diagnostic marker for MM. In MM, it promotes an angiogenic phenotype in endothelial cells, 111 promotes tumor growth and metastasis, and suppresses apoptosis. 112 CD138 overexpression has been associated with poor survival in patients with non-GCB DLBCL. 113 Indatuximab ravtansine (BT062) is an anti-CD138 mAb linked to a maytansinoid payload by a disulfide-containing linker. 114 In a phase I/II study, 29 patients with R/R MM who had developed progression after previous immunomodulatory drugs and proteasome inhibitor therapies were treated with indatuximab ravtansine. 107 Of 23 efficacy-evaluable patients, only 1 patient achieved a response (partial response); stable disease was noted for an additional 11 patients (48%). The median PFS for these patients was 112 days. Another phase I/II study investigated indatuximab ravtansine combined with low-dose dexamethasone and either lenalidomide or pomalidomide in patients with R/R MM, including patients previously treated with immunomodulatory imide drugs and/or dexamethasone. 108 At the MTD, the ORR for those treated with indatuximab ravtansine, lenalidomide, and dexamethasone was 77%, with a 21-month mDOR. In patients previously treated with lenalidomide and bortezomib who had developed progression within 60 days of treatment, the ORR was 54% (8% CR). Among patients treated with indatuximab ravtansine, pomalidomide, and dexamethasone, all of whom had had previous lenalidomide or bortezomib exposure with disease progression within 60 days of treatment, the ORR was 79%, with the mDOR not reached at 7.5 months. AEs included diarrhea, fatigue, and nausea and were mostly grade 1/2. No trials of indatuximab ravtansine are currently recruiting.
Anti-CD269 (B-cell Maturation Agent) ADCs
CD269, more commonly known as BCMA (B-cell maturation agent), is a type III transmembrane protein and member of the TNF superfamily that regulates B-cell maturation and differentiation into plasma cells. It is expressed on B cells and normal and malignant plasma cells, with universal expression in MM that is maintained through disease relapse. 115 High serum levels of BCMA independently predict for shorter PFS and OS in MM.
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GSK2857916 consists of an afucosylated anti-BCMA antibody conjugated to an MMAF payload by a noncleavable linker. In xenograft models of MM, it rapidly eliminated MM cells, with the mice remaining tumor free for 3.5 months. 117 In a first-inhuman phase I study of GSK2857916 in R/R MM and other BCMA-expressing hematologic malignancies, patients were required to have undergone SCT or be SCT ineligible, to have been previously treated with alkylators, proteasome inhibitors, and immunomodulatory imide drugs and to have developed disease progression within 60 days of the last therapy. 109 In the dose expansion part of the study, 35 patients (57% with ! 5 previous lines of therapy) were treated at the recommended phase II dose. The ORR was 60% (9% stringent CR/CR), and the median PFS was 7.9 months. Reversible corneal events, mostly grade 1/2, were common (63%); the most frequent grade ! 3 AEs were hematologic, and 23% of patients experienced infusion-related reactions. No premedication was used. In November 2017, GSK2857916 was granted breakthrough therapy designation by the FDA for R/R MM. 118 No other anti-BCMA ADCs are currently in clinical testing for hematologic malignancies; however, a preclinical ADC targeted to enter the clinic in late 2018 has been reported. 119 HDP-101 is an anti-BCMA mAb site-specifically conjugated to a derivative of amanitin, the toxic component of death cap mushrooms, through a noncleavable linker. It has been reported to induce complete remission after a single injection in xenograft models of MM, and the compound was well tolerated in cynomolgus monkeys.
Anti-CD319 (SLAMF7, CS1) ADCs CD319, also known as SLAMF7 and CS1, is an immunoglobulin superfamily member universally expressed on MM cells that promotes adhesion of MM cells to bone marrow stromal cells. 120 The clinical utility of targeting CD319 was demonstrated by the mAb elotuzumab, which has been approved for use in combination with lenalidomide and dexamethasone in patients with MM who have received 1 to 3 previous therapies. 121 ABBV-838 is an anti-CD319 mAb conjugated to an MMAE payload by a cathepsincleavable linker (Table 1) . 122 ABBV-838 binds to a unique epitope of CD319 and was active in xenograft models of MM. The compound was investigated in a phase I study of patients with heavily pretreated R/R MM (ClinicalTrials.gov identifier, NCT02462525). However, the study was terminated owing to a "No Go" decision by its sponsor.
Anti-CD352 (SLAMF6) ADCs
CD352, also known as SLAMF6 and NTB-A, is a type I transmembrane member of the Ig2 superfamily expressed on the surface of NK, T, and B cells is a positive regulator of NK cell function, and modulates T follicular helper-cell and germinal B-cell interactions. CD352 expression was detected in 87% of MM patient samples. SGN-CD352A is an anti-CD352 mAb conjugated to a PBD dimer payload. 123 A single injection of SGN-CD352A
produced durable complete remissions in 10 of 10 mice in the MM.1R xenograft model and 9 of 10 mice in the U-266 xenograft model. This ADC is currently undergoing clinical investigation in patients with heavily pretreated R/R MM (ClinicalTrials.gov identifier, NCT02954796; Supplemental Table 1 ; available in the online version).
ADCs Targeting Other Antigens
Supplemental Table 3 (available in the online version) lists the preclinical ADCs active in animal models of B-lineage malignancies, including a number of targeting antigens that have not been described in previous sections (CD20, CD38, CD46, CD48, CD205, and human leukocyte antigeneantigen D related).
Conclusion
The development of rituximab, a monoclonal antibody with high selectivity for the CD20 antigen, led to a paradigm shift in the treatment of hematologic malignancies. Subsequent experience, however, has shown that the effectiveness of such "naked" antibodies, which target other tumor cell antigens, is frequently quite limited. Using the selectivity inherent in antibodyeantigen binding to deliver potent cytotoxins to tumor cells has consequently driven the development of clinical ADCs.
Three ADCs (ie, gemtuzumab ozogamicin, brentuximab vedotin, and inotuzumab ozogamicin) are currently used to treat hematologic malignancies, and ! 14 others are in clinical development. More than 40 clinical trials of ADCs for the treatment of B-lineage malignancies are now ongoing (Supplemental Tables 1 and 2 ; available in the online version). In addition, promising efficacy in animal models has been reported for > 12 novel ADCs, some of which are now entering clinical development (Supplemental Table 3 ; available in the online version).
The efficacy and safety of ADCs have moved in synchrony with advances in their design. Early ADCs proved to have narrow therapeutic windows, which might be attributed to a number of issues, including the choice of antigen, stability, and lack of sufficient payload potency. Importantly, they were prepared by conjugation methods that tended to produce mixtures of ADCs with heterogeneous DARs (including a DAR of 0 for the naked antibody)
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ADCs, including BV and most ADCs currently in clinical trials, overcame many of these problems but were, until recently, still produced by nonspecific methods that led to product heterogeneity. More recently, ADCs such as polatuzumab vedotin have appeared in the clinic, incorporating potent payloads stably conjugated at specific sites for defined DARs and homogeneity. Only prospective clinical testing as monotherapy and combined with standard of care agents can determine whether these newer generation ADCs sufficiently address the issues that vexed earlier ones.
As an interim measure of the clinical success of ADCs in Blineage malignancies to date, of the 20 ADCs we have reviewed, 7 have advanced into phase II trials and 6 have progressed to studies combined with other agents (Supplemental Table 2 ; available in the online version). The progression of ADCs from early-stage, singleagent studies to combination use brings with it the possibility of additive or synergistic efficacy with nonoverlapping toxicities.
As the use of ADCs becomes more widespread in the clinic, increasing interest in the issue of ADC resistance can be anticipated. Studies to date have implicated a number of potential contributory factors, including antigen downregulation, antigen mutation, drug transporter overexpression, alterations in ADC distribution or trafficking, and alterations in apoptotic or signaling pathways. 12, 125 For BV in HL, preclinical evidence has suggested that overexpression of MDR1, a drug transporter that acts to expel the payload from cells, is an important mediator of resistance. 126, 127 A phase I study (ClinicalTrials.gov identifier, NCT03013933) of its use combined with cyclosporine A and verapamil in R/R HL is currently testing this hypothesis in the clinic. In summary, ADCs have progressed from theory, through early ADCs with low therapeutic indexes, to the present, more strategically designed compounds that have begun to have a clinical impact. ADCs are off-the-shelf therapies that are readily available, easy to administer in an outpatient setting, and generally well-tolerated. In an era of many promising new therapies, several ADCs have proved to be effective in treating B-lineage malignancies, in some cases providing response rates similar to those seen with other emerging treatment options such as chimeric antigen receptor T-cell therapy. Despite advances in the management of B-cell lineage malignancies, a tremendous unmet need to expand the effective treatment arsenal for these diseases remains and necessitates further exploration of ADCs, especially in combination with other emerging therapies, to improve the outcomes for patients with B-cell malignancies.
